DuPont's Innohep Anticoagulant Approved With Once-Daily Dosing Regimen
Executive Summary
DuPont's low molecular weight heparin Innohep will enter the market as the only treatment with once-daily dosing for all patients with deep vein thrombosis. Other LMWHs have a mix of recommended dosages, which may include once-daily administration.
You may also be interested in...
DuPont Innohep
FDA objects to July 18 tinzaparin press release for implying that "Innohep is indicated for use in all [deep vein thrombosis] patients, that it is approved for monotherapy and that it is the only low molecular weight heparin that is administered once-a-day." Innohep was approved by FDA July 14 for acute DVT with or without pulmonary embolism in combination with warfarin (1"The Pink Sheet" July 24, p. 13)
DuPont Innohep
FDA objects to July 18 tinzaparin press release for implying that "Innohep is indicated for use in all [deep vein thrombosis] patients, that it is approved for monotherapy and that it is the only low molecular weight heparin that is administered once-a-day." Innohep was approved by FDA July 14 for acute DVT with or without pulmonary embolism in combination with warfarin (1"The Pink Sheet" July 24, p. 13)
Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines
The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.